Healthcare Takes A Big Step Forward With The Help of A.I.

To date, we've seen baseline AI models lay the groundwork. Tools like ChatGPT are useful, but they are still simple, proof-of-concept systems. For its next act, AI is going to help save lives. Already better than humans at a number of medical tasks, AI is ramping up to completely revolutionize healthcare.

Click here to learn more about the booming eHealth industry - and see which microcap will be at the

Manoussos Perros net worth and biography

Manoussos Perros Biography and Net Worth

Insider of Entasis Therapeutics

Manos Perros, Ph.D., has served as our chief executive officer, co-founder and director since May 2015. Prior to this, Dr. Perros worked for AstraZeneca AB as vice president and head of its infection research and early development organization from 2010 to 2015 and as site head for its research center in Waltham, Massachusetts from 2012 to 2015. Prior to joining AstraZeneca, Dr. Perros served as director of the Novartis Institute for Tropical Diseases in Singapore, and prior to that, as vice-president and chief scientific officer, antivirals, at Pfizer, Inc. A chemist by training, Dr. Perros conducted his Ph.D. work in Belgium, France and Germany, and was an associate in the Biophysics department at Yale from 1993 to 1995. Dr. Perros received the PhRMA Discoverer’s Award in 2010.

How old is Manoussos Perros?: Dr. Perros is currently 54 years old. There are 7 older executives and no younger executives at Entasis Therapeutics. The oldest executive at Entasis Therapeutics is Dr. John Patrick Mueller Ph.D., Chief Devel. Officer, who is 62 years old. Learn More on Manoussos Perros' age.
How do I contact Manoussos Perros?: The corporate mailing address for Dr. Perros and other Entasis Therapeutics executives is 35 GATEHOUSE DRIVE, WALTHAM MA, 02451. Entasis Therapeutics can also be reached via phone at (781) 810-0120 and via email at [email protected]. Learn More on Manoussos Perros' contact information.
Has Manoussos Perros been buying or selling shares of Entasis Therapeutics?: Manoussos Perros has not been actively trading shares of Entasis Therapeutics within the last three months. Most recently, Manoussos Perros sold 11,974 shares of the business's stock in a transaction on Tuesday, October 19th. The shares were sold at an average price of $3.19, for a transaction totalling $38,197.06. Learn More on Manoussos Perros' trading history.
Who are Entasis Therapeutics' active insiders?: Entasis Therapeutics' insider roster includes Elizabeth Keiley (General Counsel), and Manoussos Perros (Insider). Learn More on Entasis Therapeutics' active insiders.

Manoussos Perros Insider Trading History at Entasis Therapeutics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
10/19/2021	Sell	11,974	$3.19	$38,197.06

Manoussos Perros Buying and Selling Activity at Entasis Therapeutics

Entasis Therapeutics Company Overview

Entasis Therapeutics Holdings Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibacterial products to treat serious infections caused by multidrug-resistant pathogens in the United States. Its lead product candidate is sulbactam-durlobactam (SUL-DUR), a novel IV antibiotic that is in Phase III clinical trial for the treatment of pneumonia and bloodstream infections caused by carbapenem-resistant Acinetobacter baumannii. The company also develops Zoliflodacin, a novel orally administered molecule, which is in Phase III clinical trial for the treatment of uncomplicated gonorrhea; ETX0282CPDP, an oral drug that is in Phase I clinical trial for the treatment of urinary tract infections; and ETX0462, a drug candidate from NBP platform that is in pre-clinical stage for the treatment of multidrug-resistant gram-negative infections. The company has a license and collaboration agreement with Zai Lab (Shanghai) Co., Ltd. for the development of durlobactam and SUL-DUR; and collaboration agreement with Global Antibiotic Research and Development Partnership for the development and commercialization of a product candidate zoliflodacin. Entasis Therapeutics Holdings Inc. was founded in 2015 and is headquartered in Waltham, Massachusetts. Entasis Therapeutics Holdings Inc. operates as a subsidiary of Innoviva, Inc.

Today's Range

Now: $2.19

$2.19

50 Day Range

MA: $2.19

$2.18

$2.20

2 Week Range

Now: $2.19

$1.40

$3.88

Volume

800 shs

Average Volume

239,104 shs

Market Capitalization

$104.80 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.33